kidney disease
Boditech Med, SphingoTec Ink Commercialization Deal for Kidney Injury Test
The firms will market a point-of-care test that incorporates SphingoTec's kidney function biomarker and is designed for use on Boditech Med's AFIAS instruments.
The firm's prognostic test uses biomarker testing and clinical information to generate a score indicating a patient's risk of developing kidney disease.
Renalytix, Vector Pharma Ink Middle East Distribution Agreement
Vector Pharma will distribute Renalytix's KidneyIntelX.dkd test throughout the six countries comprising the Gulf Cooperation Council.
Renalytix Kidney Disease Test Gets FDA Clearance
The test, which assesses predictive blood-based biomarkers and electronic health record data, was first introduced in the US in late 2020 as a laboratory-developed test.
DiaSorin Gains CE Mark for Sepsis, Severe Infection Assay
The firm's immunodiagnostic assay is intended to aid diagnosis of conditions such as sepsis, septic shock, and severe kidney diseases.
Feb 8, 2023
Renalytix to Raise $20.3M in Private Placement
Oct 31, 2022
Renalytix Posts $2.9M in Revenue for Fiscal 2022
Jun 30, 2022
Renalytix Fiscal Q3 Revenues Up 31 Percent
Jun 24, 2022
Almac, AstraZeneca Strike CDx Development Pact
Oct 21, 2021
Renalytix Posts $1.5M in Revenues for Fiscal 2021
Apr 14, 2021